Novartis Pharmaceuticals said it plans to eliminate about 1,960 positions in the US ahead of the loss of patent protection for valsartan, and the cessation of a Phase 3 study for a new indication for aliskiren. The stoppage of the trial has triggered a regulatory safety review.
